Key points are not available for this paper at this time.
As for patients with mCRPC, treatment with 177Lu-PSMA-617 RTL and 177Lu-PSMA I&T gave better effects and caused fewer adverse effects than third-line treatment.
Eyben et al. (Fri,) studied this question.